Exelixis (EXEL) Acquisitions (2010 - 2011)
Exelixis (EXEL) recorded quarterly Acquisitions of $44000.0 in Q4 2011, down 98.01% quarter-over-quarter from $2.2 million in Q3 2011, and down 89.0% on a YoY basis from $400000.0 in Q4 2010.
Exelixis (EXEL) Acquisitions (2010 - 2011) Analysis & Trends
Exelixis' Acquisitions history runs 2 years deep, the most recent figure standing at $44000.0 for Q4 2011.
- In Q4 2011, Acquisitions fell 89.0% year-over-year to $44000.0; the TTM figure through Dec 2011 stood at $2.7 million (changed N/A YoY), while the FY2011 annual figure was $2.3 million, down 72.5% from the prior year.
- Acquisitions was $44000.0 for Q4 2011 at Exelixis, down from $2.2 million in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $3.3 million in Q2 2010 to a low of $44000.0 in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 44,000.00 |
| Sep 30, 2011 | 2.21 Mn |
| Dec 31, 2010 | 400,000.00 |
| Jun 30, 2010 | 3.30 Mn |